Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

SEC'Y; CHIEF COMPLIANCE & G.C.

CHIEF MEDICAL OFFICER

PRESIDENT AND CEO

CHIEF SCIENTIFIC OFF,SVP-R&D

CHIEF FINANCIAL OFFICER

President and CEO

Chief Scientific Off,SVP-R&D

Sec'y; Chief Compliance & G.C.

Chief Medical Officer

VP, Head of Accting;Controller

Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut.

Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-05	Premium	sold	Premium	Premium	Premium	SEC'Y; CHIEF COMPLIANCE & G.C.
2024-04-05	Premium	sold	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2024-02-29	Premium	sold	Premium	Premium	Premium	SEC'Y; CHIEF COMPLIANCE & G.C.
2024-02-29	Premium	sold	Premium	Premium	Premium	PRESIDENT AND CEO
2024-02-29	Premium	sold	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2024-02-08	Premium	sold	Premium	Premium	Premium	PRESIDENT AND CEO
2024-02-01	Premium	acquired	Premium	Premium	Premium	PRESIDENT AND CEO
2024-02-01	Premium	sold	Premium	Premium	Premium	PRESIDENT AND CEO
2024-02-01	Premium	acquired	Premium	Premium	Premium	CHIEF SCIENTIFIC OFF,SVP-R&D
2024-02-01	Premium	acquired	Premium	Premium	Premium	SEC'Y; CHIEF COMPLIANCE & G.C.
2024-02-01	Premium	acquired	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-02-01	Premium	acquired	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2023-11-02	Premium	sold	Premium	Premium	Premium	President and CEO
2023-08-03	Premium	sold	Premium	Premium	Premium	President and CEO
2023-06-23	Premium	sold	Premium	Premium	Premium	Chief Scientific Off,SVP-R&D
2023-06-23	Premium	sold	Premium	Premium	Premium	Sec'y; Chief Compliance & G.C.
2023-06-23	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-06-01	Premium	acquired	Premium	Premium	Premium	-
2023-06-01	Premium	acquired	Premium	Premium	Premium	-
2023-06-01	Premium	acquired	Premium	Premium	Premium	-
2023-06-01	Premium	acquired	Premium	Premium	Premium	-
2023-06-01	Premium	acquired	Premium	Premium	Premium	-
2023-05-05	Premium	sold	Premium	Premium	Premium	President and CEO
2023-04-04	Premium	sold	Premium	Premium	Premium	Chief Scientific Off,SVP-R&D
2023-04-04	Premium	sold	Premium	Premium	Premium	Chief Medical Officer

CARA - Cara Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for CARA